UAB researcher wins HudsonAlpha Prize for work on sickle cell and related blood disorders

NewsGuard 100/100 Score

Tim Townes, Ph.D., University of Alabama at Birmingham, was awarded the HudsonAlpha Prize for his work on sickle cell and related blood disorders. The $20,000 monetary award acknowledges exceptional talent, dedication and discovery by Alabama's best and brightest researchers.

The prize was announced at the HudsonAlpha Spring Benefit held April 26. "In research you never speak lightly of curing a disease, but if anyone is going to cure sickle cell, it will be Tim," said Rick Myers, Ph.D., director and president of the HudsonAlpha Institute.

Townes has dedicated his career to studying the molecular genetics of gene expression in red blood cells and exploring approaches to treat disorders such as sickle cell anemia. Townes is professor and chair of the department of biochemistry and molecular biology at UAB.

Using mice, Townes and research colleagues have been able to reprogram cells that mimic sickle cell anemia as induced pluripotent stem cells. Such cells have the potential of becoming any type of tissue. The researchers have corrected the DNA mutation in the gene associated with sickle cell disease, placed the cells with the corrected DNA back into the donor mice and had the result of healthy red blood cell production.

Townes has repeated similar steps in humans, except for having the corrected cells placed back into the donor.

Source: HudsonAlpha Institute for Biotechnology

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Discovery of new vascular cell type may pave way for novel strategies to treat cardiovascular diseases